LOC284215 Inhibitors
Chemical inhibitors of LOC284215 can act through various pathways to inhibit its activity by targeting key regulatory proteins involved in cellular signaling. Alsterpaullone, a cyclin-dependent kinase inhibitor, can prevent the phosphorylation of proteins necessary for cell cycle progression, thereby inhibiting the activity of LOC284215 if it is associated with cell cycle control. Similarly, rapamycin, by inhibiting mTOR, can downregulate the PI3K/AKT/mTOR pathway, which is integral for cell growth and proliferation, potentially affecting LOC284215's role in these processes. LY294002 and Wortmannin, both PI3K inhibitors, can further restrict AKT activation and downstream signaling, thereby influencing LOC284215's function if it is involved in PI3K/AKT-mediated pathways.
In addition to these, SB203580 and SP600125 target the p38 MAP kinase and JNK pathways, respectively. SB203580's inhibition of the p38 MAPK pathway can alter stress responses and inflammatory cytokine production, while SP600125 can affect apoptosis regulation, impacting LOC284215's activity if it is involved in these pathways. PD98059 and U0126 both inhibit MEK, with U0126 specifically targeting MEK1/2, which can suppress the activation of the MAPK/ERK pathway, a pathway known for its role in cell proliferation and differentiation, and thus can regulate LOC284215 activity if it is part of this signaling cascade. ZM336372, a RAF kinase inhibitor, and BAY 11-7082, which inhibits NF-κB activation, can also modulate the MAPK/ERK pathway and NF-κB signaling, respectively, affecting LOC284215's activity by preventing the activation of downstream proteins in these pathways. Gö6983, by inhibiting PKC isozymes, can influence pathways that regulate cell proliferation, differentiation, and apoptosis, which could regulate LOC284215's function if it interacts with PKC-dependent pathways. Finally, Dorsomorphin inhibits BMP signaling by targeting BMP type I receptors, which could affect LOC284215's function if it is part of the BMP pathway. Each inhibitor, by targeting specific signaling molecules and pathways, can modulate the activity of LOC284215 based on its involvement in these cellular processes.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs), which are essential for the cell cycle progression. Inhibition of CDKs can prevent phosphorylation of proteins required for cell cycle progression, potentially inhibiting LOC284215 if it is involved in cell cycle regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in the PI3K/AKT/mTOR pathway, which is crucial for cell growth and proliferation. Inhibition of mTOR can decrease the activity of downstream effectors that may be required for LOC284215 function in cell growth. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. It inhibits the p38 MAPK pathway, which can regulate stress responses, including inflammatory cytokines and apoptosis. If LOC284215 is involved in these pathways, SB203580 could reduce its activity by inhibiting downstream signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK in the MAPK/ERK pathway. This pathway is involved in cell proliferation and differentiation. By inhibiting MEK, PD98059 can suppress ERK activation, potentially inhibiting LOC284215 if it is part of this signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which prevents the phosphorylation and activation of AKT. Inhibition of PI3K/AKT pathway can inhibit downstream signaling events that may be involved in the functional activity of LOC284215. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in the regulation of apoptosis. If LOC284215 is implicated in apoptotic signaling, SP600125 could inhibit its function by preventing JNK-mediated signaling events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, blocking the MAPK/ERK pathway. As the MAPK/ERK pathway regulates numerous cellular processes including proliferation and differentiation, U0126 can inhibit LOC284215 function if it is associated with this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K, it can inhibit AKT activation and its downstream signaling, which could inhibit LOC284215 function if it is involved in PI3K/AKT-mediated processes. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM336372 is a RAF kinase inhibitor, which can inhibit the MAPK/ERK pathway. Inhibition of RAF and its downstream signaling can prevent the activation of proteins that are part of this pathway, potentially inhibiting LOC284215. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation by blocking the phosphorylation of IκBα. If LOC284215 is involved in NF-κB signaling, this inhibitor could reduce its activity by preventing NF-κB-mediated transcription. | ||||||